Afirma GEC Beware of small numbers in studies so far.
Afirma has a strong negative predictive value for benign. This is a major use .
Large multicenter study, multiple exclusions, variable performance in meta-analysis. No data in types of cancer in Bethesda III IV Cancer cohorts.Validation still small. Afirma has limitations. Afirma has not shown efficacy in Hurthle cell neoplasms HCN . Positve predictive value is poor for HCN.